Empatica
Empatica is recorded as a service provider in 18 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 18 of 18 trials · Latest update first
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II first-in-human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of intrathecal S230815 in paediatric participants with KCNT1-related Developmental and Epileptic Encephalopathy
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Efficacyand Safety Study Of Daxdilimab Subcutaneous Injection In Adult Participants With Inadequately Controlled Dermatomyositis Or Anti-Synthetase Inflammatory Myositis
Sponsor Horizon Therapeutics Ireland Designated Activity Company
- Start (EU)
- Latest update
- Estimated end
J2P-MC-LXBD: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J4F-MC-CYAB: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief education intervention, for the preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache.
Sponsor H. Lundbeck A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Empatica?
The 2026-10-09 snapshot links Empatica to 18 distinct CTIS trials. Recorded services include Electronic data capture, Digital biomarker device and software, Wearable device, Data management, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Empatica?
The most frequently recorded therapeutic areas are Neurology, Psychiatry, Respiratory, Immunology. Recorded phases include Phase 3, Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Empatica conducted?
The linked trials record locations in 21 countries, including France, Italy, Spain, Germany, Poland. These are trial locations, not confirmed office locations or countries where Empatica delivered services.
What can this page tell me about Empatica's trial experience?
Browse 18 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Empatica. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Empatica Inc.
- Empatica S.r.l.